as of 12-15-2025 3:54pm EST
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
| Founded: | 1994 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 318.4M | IPO Year: | N/A |
| Target Price: | $39.67 | AVG Volume (30 days): | 314.1K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.97 - $8.08 | Next Earning Date: | 11-06-2025 |
| Revenue: | $25,830,000 | Revenue Growth: | 40.39% |
| Revenue Growth (this year): | -25.23% | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
SLN Breaking Stock News: Dive into SLN Ticker-Specific Updates for Smart Investing
See how SLN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "SLN Silence Therapeutics Plc American Depository Share - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.